Four cases of recurrent breast cancer effectively treated by the new ntitumor agent, CPT-11 (irinotecan)

H. Doihara, S. Takashima, N. Yokoyama

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Four cases of recurrent breast cancer effectively treated by CPT-11 were reported. These cases had undergone previous chemotherapy including adriamycin. Nevertheless, they developed no tolerance to such therapies and displayed good responsitivity to CPT-11. Effects on metastatic lesions: One was bone and three were soft tissues was observed after the end of one course therapy. The response periods were over 210 days, 431 days, 175 days and 73 days. Thus, it was suggested that early response to drug was important clinically and was significant for enhancing the quality of life of patients. Major adverse reactions were leukopenia and gastrointestinal symptoms such as nausea, vomiting and diarrhea (Grade 2-3). However, these could be well managed by symptomatic treatment and dose modification. The results suggested that CPT-11 was an effective agent against advanced or recurrent breast cancer, and especially useful for patients who had developed a tolerance to previous therapies.

Original languageEnglish
Pages (from-to)1263-1266
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Volume21
Issue number8
Publication statusPublished - Jan 1 1994
Externally publishedYes

Keywords

  • CPT-11
  • breast cancer
  • irinotecan

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Four cases of recurrent breast cancer effectively treated by the new ntitumor agent, CPT-11 (irinotecan)'. Together they form a unique fingerprint.

  • Cite this